Pharma News

CM-24 by Purple Biotech for Melanoma: Likelihood of Approval

CM-24 is under clinical development by Purple Biotech and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CM-24’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CM-24 overview

CM-24 is under development for pancreatic cancer, melanoma, non-small cell lung cancer, metastatic pancreatic cancer, metastatic adenocarcinoma of the pancreas, pancreatic ductal adenocarcinoma, papillary thyroid cancer, and colorectal cancer. The therapeutic candidate is administered by intravenous route. CM-24 is a humanized immunoglobulin G4 (IgG4) (kappa) isotype immune-modulating monoclonal antibody that binds to CEACAM1, a protein used by cancer cells to suppress the immune system. It was under development for the treatment of metastatic melanoma, bladder, gastric, colorectal and ovarian cancer.

Purple Biotech overview

Purple Biotech, formerly known as Kitov Pharma Ltd, is a pharmaceutical company that develops novel therapies to control tumor immune evasion and drug resistance in cancer treatments. The company’s lead product candidate consensi is a non-steroidal anti-inflammatory drug is used for the treatment of osteoarthritis pain and hypertension. Its product pipeline includes CM-24 a monoclonal antibody being developed to treat non-small cell lung cancer and NT-219 a small molecule targeting head and neck cancer. The company works in partnership with Bristol Myers Squibb, Coeptis Pharmaceuticals, CSBio and Kuhnil Pharmaceuticals to develop and commercialize its pipeline products. Purple Biotech is headquartered in Tel Aviv, Israel.

For a complete picture of CM-24’s drug-specific PTSR and LoA scores, buy the report here.

Source link
#CM24 #Purple #Biotech #Melanoma #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *